GLP-1 Medications for Weight Loss Now Available!
The city of Lexington, Kentucky, currently has 3 active clinical trials seeking participants for Weight Loss research studies.
VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Read Less
Trial Updated:
08/12/2025
Locations: Viking Clinical Site #2069, Lexington, Kentucky
+1 locations
Viking Clinical Site #2069, Lexington, Kentucky
Viking Clinical Site #2040, Lexington, Kentucky
VK2735 for Weight Management Phase 3
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.
This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults who are obese (BMI ≥30 kg/m2) or overweight (BMI ≥27 kg/m2) with one or more weight related comorbid condition without Type 2 Diabetes.
Read Less
Trial Updated:
08/12/2025
Locations: Viking Clinical Site #1069, Lexington, Kentucky
+1 locations
Viking Clinical Site #1069, Lexington, Kentucky
Viking Clinical Site #1040, Lexington, Kentucky
Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity
The goal of this clinical trial is to learn if the drug semaglutide changes markers of disease risk as it relates to weight in children ages 12-15 years old who are obese (class 2 or 3). The main questions it aims to answer are:
* How do the rate of weight loss, body mass index (BMI), body composition, heart structure and function, and exercise ability interact with one another in the study population at enrollment?
* How do risk markers of disease change over the study in the study participant...
Read More
The goal of this clinical trial is to learn if the drug semaglutide changes markers of disease risk as it relates to weight in children ages 12-15 years old who are obese (class 2 or 3). The main questions it aims to answer are:
* How do the rate of weight loss, body mass index (BMI), body composition, heart structure and function, and exercise ability interact with one another in the study population at enrollment?
* How do risk markers of disease change over the study in the study participants who are given semaglutides to help with weight loss?
* Are there differences in the above factors between males and females and are there key factors to help improve the outcomes?
Participants will be given semaglutide for this study. During the course of the study, participants will:
* have two cardiac MRI scans OR two cardiac echocardiograms (one before starting semaglutide and one around 12 months after taking the drug)
* have body composition and fitness levels assessed twice (before semaglutide and around 12 months after taking it) and have urine specific gravity (USG) measured
* have extra blood drawn when labs their doctor orders are already being drawn (once at the beginning of the study, once around 6 months after enrollment, and once at the end of the study)
* have follow up visits with the study doctor
* be asked to take a pregnancy test if they are female and have started menstruation
Read Less
Ages:
Between 12 years and 17 years
Trial Updated:
07/01/2025
Locations: University of Kentucky, Lexington, Kentucky
University of Kentucky, Lexington, Kentucky
Conditions: Obesity and Overweight,
Obese Adolescents,
Weight Management,
Weight Loss,
Cardiovascular Disease Risk Factor